Biophytis Announces Phase 3 Sarcopenia Trial for BIO101 in Europe and Asia

Biophytis SA, a biotechnology company focused on age-related diseases, has unveiled its strategy for the Phase 3 SARA trial of BIO101 targeting sarcopenia. This groundbreaking trial will be the first of its kind in sarcopenia, reflecting a significant medical need due to rapidly aging populations worldwide.

The trial aims to recruit 932 sarcopenic patients, primarily from China, Japan, and Europe. These regions were chosen for both their clinical need and commercial potential, given their status as some of the fastest-aging countries. The absence of approved drugs for sarcopenia positions BIO101 to potentially dominate the market.

Biophytis plans to fund the SARA Phase 3 program through partnerships with regional pharmaceutical companies and investors in Asia. Regulatory steps in Europe are completed, while filings in China and Japan are ongoing.